CLINICAL TRIALS:

Consents

CTU Newsletter 3/2008

Click trial to get more information

Longitudinal Study of Ocular Complications of AIDS :LSOCA

A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy with Plasma HIV-1 RNA Levels =200 copies/mL.: A5212

Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections and Identifying Determinants of Responsiveness: A Pilot Study: A5232

A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment : A5235

The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen: A5241

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNETM) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts > 200 – 500/µl: POX-011

A Phase 1B, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression Potential, Pharmacokinetics and Immune Modulatory Effects of the Treatment with Aprepitant (EMEND) in HIV Infected Patients:EMEND

Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Treatment Experienced Subjects: VICTOR-E4

Pending Trials:

A Phase III, Randomized, Double-blind Study of TMC278 75mg vs Efavirenz 600mg qd in Combination with a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive HIV-1 Infected Patients: TMC278


If you have any questions regarding these studies, Please call 215-349-8092

updated 02/27/08

 

 

 
 


About UPHS   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

The University of Pennsylvania Health System, Philadelphia, PA 1-800-789-PENN © 2008, The Trustees of the University of Pennsylvania